Lars Rebien Sorensen is back as chairman of Novo Nordisk A/S following a shareholder meeting that exposed the depth of rivalry between the Danish drugmaker and US arch nemesis Pfizer Inc.

Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05.

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.

Newly-elected chairman of Wegovy-maker Novo Nordisk , Lars Rebien Sorensen, said on Friday he plans to enhance the board's ...

Eli Lilly and Novo Nordisk’s competition in weight-loss drugs has affected thousands of jobs between Charlotte and Raleigh. Who is winning?

The executive who brought Novo Nordisk A/S’s first weight-loss shot to market is coming back as chairman of the Danish ...

The boardroom shake-up, which erupted when Novo's board Chair Helge Lund and the independent members stepped down last month ...

Finally, the stock now looks reasonably valued, especially given significant clinical and commercial catalysts on the horizon ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Carol Saffran started taking Ozempic a year ago to regulate her blood sugar after other medications were ineffective. She was prediabetic, a condition in which blood sugar levels are higher than ...

Novo Nordisk and Eli Lilly deny partnership with Mangoceuticals for weight-loss drugs, causing Mangoceuticals' shares to ...

(Reuters) -Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's ...